These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

916 related items for PubMed ID: 26700585

  • 1. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J.
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [Abstract] [Full Text] [Related]

  • 2. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH.
    Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
    [Abstract] [Full Text] [Related]

  • 3. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 4. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F, Dhalwani NN, Dales J, Mani H, Khunti K, Davies MJ, Webb DR.
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [Abstract] [Full Text] [Related]

  • 5. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.
    Zintzaras E, Miligkos M, Ziakas P, Balk EM, Mademtzoglou D, Doxani C, Mprotsis T, Gowri R, Xanthopoulou P, Mpoulimari I, Kokkali C, Dimoulou G, Rodopolou P, Stefanidis I, Kent DM, Hadjigeorgiou GM.
    Clin Ther; 2014 Oct 01; 36(10):1443-53.e9. PubMed ID: 25109773
    [Abstract] [Full Text] [Related]

  • 6. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J, Mehta R, Donnelly R, Idris I.
    Ann Med; 2016 Oct 01; 48(4):224-34. PubMed ID: 26982210
    [Abstract] [Full Text] [Related]

  • 7. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
    Qian D, Zhang T, Tan X, Zheng P, Liang Z, Xie J, Jiang J, Situ B.
    PLoS One; 2018 Oct 01; 13(8):e0202563. PubMed ID: 30148851
    [Abstract] [Full Text] [Related]

  • 8. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B, Cameron C, Singh SR, Yu C, Dolovich L, Houlden R.
    Open Med; 2012 Oct 01; 6(2):e62-74. PubMed ID: 23696771
    [Abstract] [Full Text] [Related]

  • 9. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.
    BMJ; 2012 Mar 12; 344():e1369. PubMed ID: 22411919
    [Abstract] [Full Text] [Related]

  • 10. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A, Rastogi M, Dhankhar P, Bell KF.
    J Med Econ; 2018 May 12; 21(5):497-509. PubMed ID: 29376760
    [Abstract] [Full Text] [Related]

  • 11. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, Dahl M.
    Open Med; 2011 May 12; 5(1):e35-48. PubMed ID: 22046219
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
    Saulsberry WJ, Coleman CI, Mearns ES, Zaccaro E, Doleh Y, Sobieraj DM.
    Int J Clin Pract; 2015 Nov 12; 69(11):1221-35. PubMed ID: 26215321
    [Abstract] [Full Text] [Related]

  • 13. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH, Charbonnel B, Moses RG, Kalra S.
    Curr Med Res Opin; 2015 Nov 12; 31(10):1919-31. PubMed ID: 26361231
    [Abstract] [Full Text] [Related]

  • 14. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
    Takahashi M, Shibasaki M, Echizen H, Kushiyama A.
    PLoS One; 2020 Nov 12; 15(7):e0236603. PubMed ID: 32706828
    [Abstract] [Full Text] [Related]

  • 15. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.
    Zhang X, Zhao Q.
    J Hypertens; 2016 Feb 12; 34(2):167-75. PubMed ID: 26682782
    [Abstract] [Full Text] [Related]

  • 16. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB, Tang X, Han M, Yang J, Simó R.
    Metabolism; 2020 Aug 12; 109():154265. PubMed ID: 32446679
    [Abstract] [Full Text] [Related]

  • 17. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
    Dai X, Wang H, Jing Z, Fu P.
    Curr Med Res Opin; 2014 Sep 12; 30(9):1777-86. PubMed ID: 24805140
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY.
    Diabetes Metab J; 2019 Aug 12; 43(4):432-446. PubMed ID: 31237133
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
    Foroutan N, Muratov S, Levine M.
    Clin Invest Med; 2016 Apr 02; 39(2):E48-62. PubMed ID: 27040861
    [Abstract] [Full Text] [Related]

  • 20. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May 02; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.